HEALTH● LOWAug 12 · Aug 12, 2026, 2:58 PM
Acumen anticipates mid-2027 IND filing for lead EBD candidate while keeping Phase II ALTITUDE-AD topline results on track for late 2026
Seeking Alpha Tech
Acumen anticipates filing an Investigational New Drug (IND) application for its lead EBD candidate by mid-2027, with Phase II ALTITUDE-AD trial results expected in late 2026. This announcement details key milestones in the development of a potential new medical treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH28m agoHealth warnings could reduce youth’s hours spent on social mediaEuroNews [en]HEALTH59m ago14 fall ill after dining at Eaton HK hotel restaurantSouth China Morning PostHEALTH3h agoCan’t ask mosquitoes not to bite: Bengal Minister’s remark sparks criticismThe HinduHEALTH4h agoSuspected opioid overdose deaths rise as police issue new alert for Canberra | The Canberra Timescanberratimes.com.au · Australia